Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risperidone versus olanzapine for schizophrenia.

M B Jayaram1, P Hosalli, S Stroup

  • 1NHS, Becklin Centre, Alma Street, Leeds, West Yorkshire, UK, LS9 7BE. maheshbj@hotmail.com

The Cochrane Database of Systematic Reviews
|April 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reducing long acting antipsychotic injection dosage frequency: A pilot study in a community mental health team.

Journal of mental health (Abingdon, England)·2020
Same author

Pragmatic design in randomized controlled trials.

Psychological medicine·2014
Same author

Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.

Molecular psychiatry·2009
Same author

Entamoeba histolytica: genetic diversity of African strains based on the polymorphism of the serine-rich protein gene.

Experimental parasitology·2007
Same author

Cryptosporidium species: preliminary descriptions of the prevalence and genotype distribution among school children and hospital patients in the Venda region, Limpopo Province, South Africa.

Experimental parasitology·2006
Same author

Olanzapine co-therapy in bipolar disorder.

The British journal of psychiatry : the journal of mental science·2005
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
See all related articles

Risperidone and olanzapine are equally effective for schizophrenia symptom reduction. However, both antipsychotic medications cause adverse effects, with risperidone linked to more insomnia and olanzapine to higher relapse rates.

Area of Science:

  • Pharmacology and Psychiatry
  • Clinical Trial Analysis
  • Schizophrenia Treatment

Background:

  • Antipsychotic medications are standard treatments for schizophrenia.
  • Risperidone and olanzapine are frequently prescribed second-generation antipsychotics.

Purpose of the Study:

  • To compare the clinical efficacy of risperidone versus olanzapine in schizophrenia treatment.
  • To assess the safety profiles and cost-effectiveness of risperidone and olanzapine.
  • To evaluate adverse event rates and patient attrition in schizophrenia patients receiving either drug.

Main Methods:

  • Systematic review and meta-analysis of randomized clinical trials (RCTs).
  • Searched major scientific databases and contacted pharmaceutical companies for relevant studies.

Related Experiment Videos

  • Extracted and analyzed dichotomous and continuous data using random-effects models.

    • Main Results:

    • No significant difference in short-term symptom improvement between risperidone and olanzapine.
    • Olanzapine showed a trend towards lower relapse/rehospitalization rates by 12 months.
    • Both drugs commonly caused adverse events, including insomnia (more with risperidone) and sleepiness; risperidone was associated with less weight gain but more abnormal ejaculation and extrapyramidal symptoms requiring medication.

    Conclusions:

    • Risperidone and olanzapine demonstrate comparable efficacy in reducing psychotic symptoms.
    • Significant differences lie in adverse effect profiles, with implications for treatment adherence.
    • High attrition rates were observed for both treatments, underscoring the need for further research into long-term outcomes and patient-reported satisfaction.